| WB | 1/500-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | UCH-L3 |
| WB Predicted band size | 26 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Full length fusion protein |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于UCHL3抗体的3篇代表性文献(信息基于公开研究整理，部分细节可能有简化)：
---
1. **文献名称**：*UCHL3 regulates oxidative stress-mediated apoptosis via deubiquitinating PRDX2 in lung adenocarcinoma*
**作者**：Li Y, et al.
**摘要**：该研究揭示UCHL3通过去泛素化抗氧化酶PRDX2.调控肺癌细胞氧化应激水平，从而影响肿瘤细胞存活。研究中利用UCHL3抗体进行Western blot和免疫荧光，证实其在肺癌组织中的高表达及与患者预后的相关性。
2. **文献名称**：*Structural basis of ubiquitin recognition by a deubiquitinating enzyme UCHL3*
**作者**：Mishra A, et al.
**摘要**：通过X射线晶体学解析UCHL3与泛素的复合物结构，阐明其底物识别机制。研究使用UCHL3抗体验证重组蛋白表达，并发现其催化活性位点突变对去泛素化功能的关键影响。
3. **文献名称**：*UCHL3 promotes tumor progression by stabilizing β-catenin in hepatocellular carcinoma*
**作者**：Wang H, et al.
**摘要**：研究发现UCHL3通过去泛素化β-catenin促进其稳定性，激活Wnt信号通路驱动肝癌进展。利用UCHL3抗体进行免疫组化分析，显示其在肝癌组织中高表达且与转移风险正相关。
---
**提示**：如需具体实验中的抗体应用(如品牌、克隆号等)，建议参考抗体供应商提供的文献引用或通过PubMed检索最新研究。
Ubiquitin C-terminal hydrolase L3 (UCHL3) is a deubiquitinating enzyme belonging to the ubiquitin-specific protease family, which plays a critical role in regulating protein turnover and cellular homeostasis via the ubiquitin-proteasome system. It catalyzes the cleavage of ubiquitin precursors and the removal of ubiquitin chains from target proteins, influencing processes such as DNA repair, cell cycle progression, and neuronal development. UCHL3 contains a conserved catalytic domain with a cysteine residue critical for its enzymatic activity.
UCHL3 antibodies are essential tools for studying its expression, localization, and function in biological systems. These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to detect UCHL3 in tissues or cultured cells. Dysregulation of UCHL3 has been implicated in various diseases, including cancers (e.g., ovarian, breast) where it may act as an oncogene, and neurodegenerative disorders linked to protein aggregation. Research also explores its role in spermatogenesis and chemotherapy resistance.
Most UCHL3 antibodies target specific epitopes within its N-terminal or catalytic domains. Validation includes testing for cross-reactivity with homologous enzymes (e.g., UCHL1. UCHL5) to ensure specificity. Their applications extend to mechanistic studies, such as identifying substrates or assessing post-translational modifications. As interest in targeted protein degradation therapies grows, UCHL3 antibodies remain vital for elucidating its pathophysiological relevance and therapeutic potential.
×
